{"id":1001,"date":"2020-10-08T11:53:48","date_gmt":"2020-10-08T09:53:48","guid":{"rendered":"https:\/\/lungo2.fr\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/"},"modified":"2021-01-19T11:24:20","modified_gmt":"2021-01-19T10:24:20","slug":"first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center","status":"publish","type":"post","link":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/","title":{"rendered":"First patient in the A2 cohort of the PDC*line Pharma Phase I\/II trial at our Clinical Research Center"},"content":{"rendered":"<p>PDC*line Pharma recently announced that two new patient cohorts have been opened in the Phase I\/II clinical trial PDC-LUNG-101 for its therapeutic vaccine candidate PDC*lung01 in non-small cell lung cancer (NSCLC) (NCT03970746). PDC*line Pharma is a biotechnology company developing a new class of novel, potent and easily industrialized active anti-cancer immunotherapies.<\/p>\n<p>The first patient having received the drug candidate PDC*lung01 in monotherapy at &#8220;high dose&#8221; is under the supervision of Pr. Jaafar Bennouna, medical oncologist at the CHU of Nantes.<\/p>\n<p>PDC*lung01 is a cell suspension composed of a mixture of seven active ingredients in identical proportions. Each is made up of irradiated human plasmacytoid dendritic cells (PDC*line) loaded with a different synthetic peptide restricted to the HLA-A*02:01 serotype, derived from tumor antigens.<\/p>\n<p>PDC*line is a powerful antigen-presenting cell system that is able of priming and stimulating anti-tumor-specific cytotoxic CD8+ T cells from the patient&#8217;s immune system.<\/p>\n<p>The objectives of this phase I\/II trial (PDC-LUNG-101) are to evaluate the safety, tolerability, immunogenicity and preliminary clinical activity of the PDC*lung01 drug candidate, whether or not combined with anti-PD-1 therapy in NSCLC.<\/p>\n<p>&nbsp;<\/p>\n<div id=\"attachment_1002\" style=\"width: 196px\" class=\"wp-caption alignleft\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-1002\" class=\"wp-image-723\" src=\"https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/JBennouna-300x300.jpg\" alt=\"\" width=\"186\" height=\"186\" srcset=\"https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/JBennouna-300x300.jpg 300w, https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/JBennouna-150x150.jpg 150w, https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/JBennouna.jpg 700w\" sizes=\"auto, (max-width: 186px) 100vw, 186px\" \/><p id=\"caption-attachment-1002\" class=\"wp-caption-text\"><span style=\"font-size: 8pt;\">Pr Jaafar Bennouna, Medical oncologist, Pneumology unit, CHU de Nantes<\/span><\/p><\/div>\n<p>\u00ab The Nantes University Hospital is very active in this clinical trial. We are pleased to have started the administration of the first patient in the A2 cohort of the PDC*line Pharma Phase I\/II trial at our clinical research center,&#8221; said the Prof. Jaafar Bennouna, medical oncologist at the CHU de Nantes (France)\u201d.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PDC*line Pharma recently announced that two new patient cohorts have been opened in the Phase I\/II clinical trial PDC-LUNG-101 for its therapeutic vaccine candidate PDC*lung01 in non-small&#8230; <br \/><a class=\"readmore\" href=\"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/\">Read more<\/a><\/p>\n","protected":false},"author":4,"featured_media":1004,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"class_list":["post-1001","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First patient in the A2 cohort of the PDC*line Pharma Phase I\/II trial at our Clinical Research Center - LungO2<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First patient in the A2 cohort of the PDC*line Pharma Phase I\/II trial at our Clinical Research Center - LungO2\" \/>\n<meta property=\"og:description\" content=\"PDC*line Pharma recently announced that two new patient cohorts have been opened in the Phase I\/II clinical trial PDC-LUNG-101 for its therapeutic vaccine candidate PDC*lung01 in non-small... Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/\" \/>\n<meta property=\"og:site_name\" content=\"LungO2\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-08T09:53:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-01-19T10:24:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/vaccination.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"734\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Aurore Foureau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Aurore Foureau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/\"},\"author\":{\"name\":\"Aurore Foureau\",\"@id\":\"\\\/#\\\/schema\\\/person\\\/a61192e4627121ab6ad6b9ab55703fbc\"},\"headline\":\"First patient in the A2 cohort of the PDC*line Pharma Phase I\\\/II trial at our Clinical Research Center\",\"datePublished\":\"2020-10-08T09:53:48+00:00\",\"dateModified\":\"2021-01-19T10:24:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/\"},\"wordCount\":285,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lungo2.fr\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/vaccination.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/\",\"url\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/\",\"name\":\"First patient in the A2 cohort of the PDC*line Pharma Phase I\\\/II trial at our Clinical Research Center - LungO2\",\"isPartOf\":{\"@id\":\"\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lungo2.fr\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/vaccination.jpg\",\"datePublished\":\"2020-10-08T09:53:48+00:00\",\"dateModified\":\"2021-01-19T10:24:20+00:00\",\"author\":{\"@id\":\"\\\/#\\\/schema\\\/person\\\/a61192e4627121ab6ad6b9ab55703fbc\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lungo2.fr\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/vaccination.jpg\",\"contentUrl\":\"https:\\\/\\\/lungo2.fr\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/vaccination.jpg\",\"width\":1920,\"height\":734},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First patient in the A2 cohort of the PDC*line Pharma Phase I\\\/II trial at our Clinical Research Center\"}]},{\"@type\":\"WebSite\",\"@id\":\"\\\/#website\",\"url\":\"\\\/\",\"name\":\"LungO2\",\"description\":\"Promouvoir la recherche respiratoire Nantaise dans le monde\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"\\\/#\\\/schema\\\/person\\\/a61192e4627121ab6ad6b9ab55703fbc\",\"name\":\"Aurore Foureau\",\"url\":\"https:\\\/\\\/lungo2.fr\\\/en\\\/author\\\/aurore\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First patient in the A2 cohort of the PDC*line Pharma Phase I\/II trial at our Clinical Research Center - LungO2","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/","og_locale":"en_US","og_type":"article","og_title":"First patient in the A2 cohort of the PDC*line Pharma Phase I\/II trial at our Clinical Research Center - LungO2","og_description":"PDC*line Pharma recently announced that two new patient cohorts have been opened in the Phase I\/II clinical trial PDC-LUNG-101 for its therapeutic vaccine candidate PDC*lung01 in non-small... Read more","og_url":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/","og_site_name":"LungO2","article_published_time":"2020-10-08T09:53:48+00:00","article_modified_time":"2021-01-19T10:24:20+00:00","og_image":[{"width":1920,"height":734,"url":"https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/vaccination.jpg","type":"image\/jpeg"}],"author":"Aurore Foureau","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Aurore Foureau","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/#article","isPartOf":{"@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/"},"author":{"name":"Aurore Foureau","@id":"\/#\/schema\/person\/a61192e4627121ab6ad6b9ab55703fbc"},"headline":"First patient in the A2 cohort of the PDC*line Pharma Phase I\/II trial at our Clinical Research Center","datePublished":"2020-10-08T09:53:48+00:00","dateModified":"2021-01-19T10:24:20+00:00","mainEntityOfPage":{"@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/"},"wordCount":285,"commentCount":0,"image":{"@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/#primaryimage"},"thumbnailUrl":"https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/vaccination.jpg","articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/","url":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/","name":"First patient in the A2 cohort of the PDC*line Pharma Phase I\/II trial at our Clinical Research Center - LungO2","isPartOf":{"@id":"\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/#primaryimage"},"image":{"@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/#primaryimage"},"thumbnailUrl":"https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/vaccination.jpg","datePublished":"2020-10-08T09:53:48+00:00","dateModified":"2021-01-19T10:24:20+00:00","author":{"@id":"\/#\/schema\/person\/a61192e4627121ab6ad6b9ab55703fbc"},"breadcrumb":{"@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/#primaryimage","url":"https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/vaccination.jpg","contentUrl":"https:\/\/lungo2.fr\/wp-content\/uploads\/2020\/10\/vaccination.jpg","width":1920,"height":734},{"@type":"BreadcrumbList","@id":"https:\/\/lungo2.fr\/en\/first-patient-in-the-a2-cohort-of-the-pdcline-pharma-phase-i-ii-trial-at-our-clinical-research-center\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/lungo2.fr\/en\/"},{"@type":"ListItem","position":2,"name":"First patient in the A2 cohort of the PDC*line Pharma Phase I\/II trial at our Clinical Research Center"}]},{"@type":"WebSite","@id":"\/#website","url":"\/","name":"LungO2","description":"Promouvoir la recherche respiratoire Nantaise dans le monde","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"\/#\/schema\/person\/a61192e4627121ab6ad6b9ab55703fbc","name":"Aurore Foureau","url":"https:\/\/lungo2.fr\/en\/author\/aurore\/"}]}},"_links":{"self":[{"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/posts\/1001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/comments?post=1001"}],"version-history":[{"count":7,"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/posts\/1001\/revisions"}],"predecessor-version":[{"id":1281,"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/posts\/1001\/revisions\/1281"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/media\/1004"}],"wp:attachment":[{"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/media?parent=1001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/categories?post=1001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lungo2.fr\/en\/wp-json\/wp\/v2\/tags?post=1001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}